Q32 Bio Inc (QTTB) Stock Price, Quote & News - Mboum

Company Profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic derm...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 999 0232

Website: www.q32bio.com

Address:

830 Winter Street, Waltham, United States

Bearpicks Aug. 18 at 2:50 PM

$QTTB FDA news anytime soon? This can fly

0 · Reply

WallStreetPicks Aug. 11 at 4:50 PM

$QTTB Hidden Gem under $2 with a small float, a good pr brings this above 4 to 5 area

0 · Reply

aquira Aug. 7 at 2:43 PM

$QTTB fuck this sheeeettt

0 · Reply

d_risk Aug. 6 at 1:28 PM

$QTTB - Q32 Bio Inc. Common Stock - 10Q - Updated Risk Factors QTTB’s 2025 10-Q risk factors highlight ongoing losses, limited operating history, clinical trial uncertainties, regulatory and commercialization challenges, heavy reliance on bempikibart, expanded IP and patent risks, third-party dependencies, evolving regulatory landscapes, healthcare compliance, and cybersecurity vulnerabilities. #Biotechnology #Cybersecurity #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/QTTB/10-Q/2025-08-06

1 · Reply

Bluesclues692 Aug. 1 at 2:55 AM

$QTTB Hey $OPEN Heres a potential multibagger that may pop off sooner than $OPEN Do some DD

0 · Reply

juananthebest Jul. 31 at 3:34 PM

$QTTB will junto To 20

0 · Reply

juananthebest Jul. 31 at 3:34 PM

$QTTB FDA News PR today or tomorrow

0 · Reply

Rampageusa Jul. 24 at 2:16 PM

$QTTB & $DARA two to watch..

0 · Reply

Rampageusa Jul. 23 at 4:44 PM

$QTTB 3.75 is what we are looking for

0 · Reply

p983 Jul. 22 at 6:10 PM

$QTTB IN 2.23!!!

0 · Reply

Latest News on QTTB

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 6:59 AM EDT - 13 days ago

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Jun 25, 2025, 6:59 AM EDT - 7 weeks ago

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 6:59 AM EDT - 3 months ago

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Apr 30, 2025, 6:59 AM EDT - 3 months ago

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Apr 16, 2025, 6:59 AM EDT - 4 months ago

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Mar 11, 2025, 6:59 AM EDT - 5 months ago

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Mar 8, 2025, 11:00 AM EST - 5 months ago

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Feb 28, 2025, 9:00 AM EST - 6 months ago

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Q32 Bio to Participate in Upcoming March Investor Conferences

Feb 26, 2025, 6:59 AM EST - 6 months ago

Q32 Bio to Participate in Upcoming March Investor Conferences

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Feb 10, 2025, 4:05 PM EST - 6 months ago

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 6 months ago

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?

Dec 11, 2024, 11:32 AM EST - 8 months ago

Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Dec 10, 2024, 4:05 PM EST - 8 months ago

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 6:59 AM EST - 10 months ago

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 6:59 AM EST - 10 months ago

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Oct 14, 2024, 6:59 AM EDT - 11 months ago

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Q32 Bio to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097

Aug 29, 2024, 3:40 AM EDT - 1 year ago

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

Aug 1, 2024, 4:54 PM EDT - 1 year ago

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

AIU COMM EBS HE HUMA SAVA SERV

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Jul 9, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Q32 Bio Joins Russell 3000® Index

Jul 1, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Joins Russell 3000® Index

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

Mar 25, 2024, 4:15 PM EDT - 1 year ago

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

Bearpicks Aug. 18 at 2:50 PM

$QTTB FDA news anytime soon? This can fly

0 · Reply

WallStreetPicks Aug. 11 at 4:50 PM

$QTTB Hidden Gem under $2 with a small float, a good pr brings this above 4 to 5 area

0 · Reply

aquira Aug. 7 at 2:43 PM

$QTTB fuck this sheeeettt

0 · Reply

d_risk Aug. 6 at 1:28 PM

$QTTB - Q32 Bio Inc. Common Stock - 10Q - Updated Risk Factors QTTB’s 2025 10-Q risk factors highlight ongoing losses, limited operating history, clinical trial uncertainties, regulatory and commercialization challenges, heavy reliance on bempikibart, expanded IP and patent risks, third-party dependencies, evolving regulatory landscapes, healthcare compliance, and cybersecurity vulnerabilities. #Biotechnology #Cybersecurity #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/QTTB/10-Q/2025-08-06

1 · Reply

Bluesclues692 Aug. 1 at 2:55 AM

$QTTB Hey $OPEN Heres a potential multibagger that may pop off sooner than $OPEN Do some DD

0 · Reply

juananthebest Jul. 31 at 3:34 PM

$QTTB will junto To 20

0 · Reply

juananthebest Jul. 31 at 3:34 PM

$QTTB FDA News PR today or tomorrow

0 · Reply

Rampageusa Jul. 24 at 2:16 PM

$QTTB & $DARA two to watch..

0 · Reply

Rampageusa Jul. 23 at 4:44 PM

$QTTB 3.75 is what we are looking for

0 · Reply

p983 Jul. 22 at 6:10 PM

$QTTB IN 2.23!!!

0 · Reply

p983 Jul. 22 at 2:39 PM

$QTTB I left, we'll see if we can get better prices again.

0 · Reply

MGeronimo Jul. 21 at 3:21 PM

$QTTB ADDED AT 2.23

0 · Reply

p983 Jul. 21 at 2:12 PM

$QTTB I'm in guys, average 2.27 taking everything you're giving me yesss!!

0 · Reply

Svetli_stock Jul. 18 at 3:26 PM

$QTTB today 2.8$-3$, next week 4$

1 · Reply

Tropics8 Jul. 17 at 5:53 PM

$QTTB 👀

2 · Reply

Bromberger Jul. 17 at 4:33 PM

$QTTB ok. The pumping is over. Back to $1

0 · Reply

silentmaxx Jul. 17 at 4:07 PM

0 · Reply

MGeronimo Jul. 17 at 2:39 PM

$QTTB adding the dip

0 · Reply

silentmaxx Jul. 17 at 2:05 PM

0 · Reply

Tropics8 Jul. 17 at 1:34 PM

$QTTB so rigged right now and wild! A put at $5 just made 25000%+ profits

0 · Reply

MGeronimo Jul. 17 at 1:32 PM

$QTTB In at 2.76 5x normal on fast track drug news

0 · Reply

Tropics8 Jul. 17 at 1:05 PM

$QTTB Good Day 🎉 $ZBAI $OPEN $VCLN

0 · Reply